Beximco Pharmaceuticals (LSE:BXP), the AIM-listed manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, grew net revenue 10.7% to BDT 49,120.4 million (£295.6 million) for the year ended 30 June 2025, from BDT 44,391.7 million (£286.6 million) a year earlier.
The standout move was in exports, where sales surged 37.7% to BDT 4,073.5 million (£24.5 million), against a more modest 8.7% rise in domestic sales to BDT 45,046.9 million (£271.1 million).
Profit after tax climbed 19.3% to BDT 6,998.9 million (£42.1 million), outpacing the revenue growth rate and suggesting improved operating leverage across the period.
Earnings per share rose to BDT 15.56 from BDT 13.07 in the prior year.
Cash and cash equivalents at 30 June 2025 stood at BDT 1,700.1 million, roughly double the BDT 854.1 million held a year earlier.
No forward guidance was included in the results statement.
